Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (49)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brown, A. J.
Right arrow Articles by Slatopolsky, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, A. J.
Right arrow Articles by Slatopolsky, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 10-19
© 2002 European Renal Association-European Dialysis and Transplant Association


Vitamin D analogues for secondary hyperparathyroidism

Alex J. Brown, Adriana S. Dusso and Eduardo Slatopolsky

Renal Division, Washington University School of Medicine, St Louis, Missouri, USA

Abstract

Secondary hyperparathyroidism (2HPT), a common disorder in patients with chronic renal failure, develops in response to phosphate retention and low serum 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol). Replacement therapy with calcitriol or its precursor 1{alpha}-hydroxyvitamin D3 (1{alpha}OHD3, alfacalcidol) often produces hypercalcaemia, especially when combined with calcium-based phosphate binders. In addition, these vitamin D compounds can aggravate the hyperphosphataemia in these patients. Several vitamin D analogues have been developed that retain the direct suppressive action of 1,25(OH)2D3 on the parathyroid glands but have less calcaemic activity, thereby offering a safer and more effective means of controlling 2HPT. 1,25-Dihydroxy-19-norvitamin D2 (19-norD2) and 1{alpha}-hydroxyvitamin D2 (1{alpha}OHD2) are available in the US and 1,25-dihydroxy-22-oxavitamin D3 (22-oxacalcitriol, OCT) and 1,25-dihydroxy-26,26,26,27,27,27-hexafluorovitamin D3 (1,25(OH)226,27F6 D3, falecalcitriol) have been approved for use in Japan. Animal studies have demonstrated that OCT and 19-norD2 have a wider therapeutic window for suppression of parathyroid hormone (PTH) because of their lower calcaemic and phosphataemic activities. The low calcaemic activity of OCT has been attributed to its rapid clearance, which prevents sustained effects on intestinal calcium absorption and bone resorption, but still allows a prolonged suppression of PTH gene expression and parathyroid cell growth. The calcaemic activity of 19-norD2 diminishes with the duration of treatment by as yet unknown mechanisms. The lower toxicity of 1{alpha}OHD2, compared with 1{alpha}OHD3, has also been noted with chronic, but not acute administration, perhaps due to differential metabolism. The unique actions of falecalcitriol may also result from an altered metabolism. A clear understanding of the molecular basis for the selectivity of vitamin D analogues on parathyroid function may allow the design of even more effective analogues.

Keywords: calcium; chronic renal failure; OCT; parathyroid hormone; secondary hyperparathyroidism; vitamin D analogues

Notes

Correspondence and offprint requests to: Alex J. Brown, PhD, Box 8126, 660 S Euclid, St Louis, MO 63110, USA. Email: abrown{at}imgate.wustl.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
W. Noonan, K. Koch, M. Nakane, J. Ma, D. Dixon, A. Bolin, and G. Reinhart
Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats
Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3824 - 3830.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
A. L. M. de Francisco and F. Carrera
A New Paradigm for the Treatment of Secondary Hyperparathyroidism
NDT Plus, January 1, 2008; 1(suppl_1): i24 - i28.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.